A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung
A phase 1/2 trial of PM8002 in small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
Overview
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07325136 by Bristol-Myers Squibb, with 240 participants planned, started 2026-02-03 and due to reach its primary completion in 2029-04-23. Interventions recorded: BMS-986525, Pumitamig. Conditions listed: Relapsed/Refractory Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
- TrialA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
- TrialA Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Shares PM8002, Bristol Myers Squibb.
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Shares PM8002, Small-cell lung cancer.
- TrialA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres
Shares PM8002, Bristol Myers Squibb.
- TrialPM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Shares PM8002, Small-cell lung cancer.
- TrialA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced
Shares PM8002, Small-cell lung cancer.
- TrialA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.